Advertisement
U.S. markets open in 4 hours 25 minutes

Johnson & Johnson (JNJ.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
146.00+0.60 (+0.41%)
As of 09:24AM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close145.40
Open145.70
Bid146.00 x 30000
Ask146.40 x 30000
Day's Range145.70 - 146.00
52 Week Range135.00 - 160.40
Volume160
Avg. Volume821
Market Cap352.869B
Beta (5Y Monthly)0.53
PE Ratio (TTM)30.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield4.39 (3.02%)
Ex-Dividend DateFeb 16, 2024
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for JNJ.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

      ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & JohnsonSOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge. Thi

    • Business Wire

      Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

      NEW BRUNSWICK, N.J., March 11, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executi

    • Business Wire

      Johnson & Johnson Completes Acquisition of Ambrx

      NEW BRUNSWICK, N.J., March 07, 2024--Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, as announced on January 8, 2024. The